Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review

Zhou, Zaigang; Wang, Haoxiang; Li, Jie; Jiang, Xin; Li, Zhangping; Shen, Jianliang

doi:10.1016/j.ijbiomac.2023.127911

Cited by 13 publications

(5 citation statements)

References 253 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the discovery of the AMPK pathway as a central regulator of energy homeostasis, many exciting insights into its regulation mechanism, structure, and physiological roles have been revealed. , Recently, it has revealed that the AMPK pathway played a critical role in regulating cell–cell adhesion and breast cancer metastasis at least partly by reducing TGF-β expression. − In this study, we proved that MHI-TMX@ALB nanoparticles effectively inhibited 4T1 tumor lung metastasis (Figures , ). In addition, MHI-TMX@ALB nanoparticles could also selectively accumulate in the 4T1 metastasis foci, meaning that MHI-TMX@ALB nanoparticles may also inhibit the growth of 4T1 metastasis foci when formed (Figures , ).…”

Section: Discussionmentioning

confidence: 59%

Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance

Jiang,

Yi,

et al. 2024

ACS Nano

Self Cite

View full text Add to dashboard Cite

Currently, limited photosensitizers possess the capacity to reverse tumor hypoxia and reduce programmed death ligand-1 (PD-L1) and transforming growth factor-β (TGF-β) expression simultaneously, hindering the perfect photodynamic therapy (PDT) effect due to acquired immune resistance and the tumor hypoxic microenvironment. To tackle these challenges, in this research, we demonstrated that mitochondrial energy metabolism depression can be utilized as an innovative and efficient approach for reducing the expression of PD-L1 and TGF-β simultaneously, which may offer a design strategy for a more ideal PDT nanosystem. Through proteomic analysis of 5637 cells, we revealed that tamoxifen (TMX) can incredibly regulate PD-L1 expression in tumor cells. Then, to selectively deliver clinically used mitochondrial energy metabolism depressant TMX to solid tumors as well as design an ideal PDT nanosystem, we synthesized MHI-TMX@ALB by combining a mitochondria-targeted heptamethine cyanine PDT-dye MHI with TMX through self-assembly with albumin (ALB). Interestingly enough, the MHI-TMX@ALB nanoparticle demonstrated effective reversion of tumor hypoxia and inhibition of PD-L1 protein expression at a lower dosage (7.5 times to TMX), which then enhanced the efficacy of photodynamic immunotherapy via enhancing T-cell infiltration. Apart from this, by leveraging the heptamethine dye's targeting capacity toward tumors and TMX's role in suppressing TGF-β, MHI-TMX@ALB also more effectively mitigated 4T1 tumor lung metastasis development. All in all, the MHI-TMX@ALB nanoparticle could be used as a multifunctional economical PD-L1 and TGF-β codepression immune-regulating strategy, broadening the potential clinical applications for a more ideal PDT nanosystem.

show abstract

Section: Discussionmentioning

confidence: 59%

Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance

Jiang,

Yi,

et al. 2024

ACS Nano

Self Cite

View full text Add to dashboard Cite

show abstract

“…Under investigation are methods to sensitize radiotherapy by depressing PD-L1 expression and reversing tumor hypoxia, since PD-L1 may be upregulated secondary to radiation, thus limiting response to treatment. The antineoplastic agent lonidamine (LND) is brought into the cells using nanoparticles [ 41 , 42 ]. Prospective individualized TARE planning and treatment with multi-compartment, voxel-based dosimetry models may improve clinical outcomes.…”

Section: Discussionmentioning

confidence: 99%

Transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: A Comparison of Palliative with Bridging-to-Transplant Concepts

Schönherr,

Seifert,

Gühne

et al. 2024

Cancers

View full text Add to dashboard Cite

We investigated transarterial radioembolization (TARE) as a palliative measure and bridging-to-transplant therapy in hepatocellular carcinoma (HCC) patients. A total of 167 patients (50 bridging, 117 palliative) with 245 TARE procedures were assessed. Fourteen patients underwent subsequent liver transplantation (LT). Patients undergoing LT exhibited significantly prolonged progression-free survival (PFS) compared to those with bridging-without-transplant (p = 0.033). No significant differences were observed between patients with bridging-without-transplant and palliative cases (p = 0.116). Median overall survival (OS) post-TARE was 16.6 months, with estimated OS rates at 6/12 months of 82.0%/60.5%, respectively. Patients who underwent LT demonstrated statistically significantly longer OS compared to those with bridging-without-transplant (p = 0.001). No marked outcome distinctions were found between bridging-without-transplant and palliative groups. The findings underscored the superiority of LT over alternative treatments. TARE served as an important component in non-LT scenarios, allowing for subsequent therapeutic options. The study reflected the highly variable and complex situations of patients with HCC, emphasizing the need for further investigations to define an optimal multimodal approach.

show abstract

“…Also, the dual-immune regulation strategy targeting tumor-responsive PD-L1 and Cox-2 proved to be more effective compared to strategies focused solely on PD-L1 or Cox-2 in inhibiting tumor growth, preventing metastasis, and avoiding relapse. This was observed even in the case of low immunogenic tumors, such as 4T1 breast cancer [18].…”

Section: Pembrolizumabmentioning

confidence: 97%

“…Additionally, recent evidence has demonstrated that intracellular PD-L1, functioning as a ribonucleic acid (RNA)-binding protein, can modulate the stability of messenger RNA (mRNA) associated with DNA damage genes. This regulation enhances cellular resistance to DNA damage [18]. A substantial increase in the CD8+ T-cell/eTreg cell ratio was noted in patients undergoing anti-PD-1 therapy, which was linked to a significant increase in the frequency of CD8+ T-cells and a simultaneous reduction in the frequency of eTreg cells within tumor-infiltrating lymphocytes.…”

Section: Pd-1mentioning

confidence: 99%

Therapeutic Immunomodulation in Gastric Cancer

Akkanapally,

Bai,

Basu

2024

Cancers

View full text Add to dashboard Cite

Gastric carcinoma, being one of the most prevalent types of solid tumors, has emerged as the third leading cause of death worldwide. The symptoms of gastric cancer (GC) are typically complex, which makes early detection challenging. Immune checkpoint inhibition has become the new standard targeted therapy for advanced or metastatic GC. It is currently being explored in various combinations, both with and without chemotherapy, across multiple therapies in clinical trials. Immunotherapy can stimulate immune responses in GC patients, leading to the destruction of cancer cells. Compared with traditional therapies, immunotherapy has shown strong effectiveness with tolerable toxicity levels. Hence, this innovative approach to the treatment of advanced GC has gained popularity. In this review, we have outlined the recent advancements in immunotherapy for advanced GC, including immune checkpoint inhibitors, cancer vaccines, vascular endothelial growth factor-A inhibitors, and chimeric antigen receptor T-cell therapy. Our current emphasis is on examining the immunotherapies presently employed in clinical settings, addressing the existing challenges associated with these therapeutic approaches, and exploring promising strategies to overcome their limitations.

show abstract

Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review

Cited by 13 publications

References 253 publications

Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance

Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance

Transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: A Comparison of Palliative with Bridging-to-Transplant Concepts

Therapeutic Immunomodulation in Gastric Cancer

Contact Info

Product

Resources

About